Lin−CCR2+ hematopoietic stem and progenitor cells overcome resistance to PD-1 blockade
Brain tumors are difficult to treat using existing immunotherapeutic strategies. Here, the authors show that in brain tumors resistant to PD-1 blockade, HSCs expressing CCR2+ can reverse treatment resistance and sensitizes mice to immunotherapy.
Guardado en:
Autores principales: | Catherine T. Flores, Tyler J. Wildes, Jeffrey A. Drake, Ginger L. Moore, Bayli DiVita Dean, Rebecca S. Abraham, Duane A. Mitchell |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e858bb0fbd22476293c8ca108b30024b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
por: Florie Bertrand, et al.
Publicado: (2017) -
Preventive CCL2/CCR2 Axis Blockade Suppresses Osteoclast Activity in a Mouse Model of Rheumatoid Arthritis by Reducing Homing of CCR2hi Osteoclast Progenitors to the Affected Bone
por: Darja Flegar, et al.
Publicado: (2021) -
Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer
por: Grégoire de Streel, et al.
Publicado: (2020) -
TGF-β inhibition can overcome cancer primary resistance to PD-1 blockade: A mathematical model.
por: Nourridine Siewe, et al.
Publicado: (2021) -
Targeting IFNα to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance
por: Yong Liang, et al.
Publicado: (2018)